Female Sexual Dysfunction Treatment Market Size, Share & Industry Analysis, By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy, and Others), By Disease (Hypoactive Sexual Desire Disorder (HSDD), Dyspareunia, and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: March 12, 2025 | Format: PDF | Report ID: FBI100850

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2025-2032
Historical Period	2019-2023
Unit	Value (USD million)
Growth Rate	CAGR of 13.8% from 2025-2032
Segmentation	By Drug Flibanserin Bremelanotide Ospemifene Estrogen Therapy Others
	By Disease Hypoactive Sexual Desire Disorder (HSDD) Dyspareunia Others
	By Route of Administration Oral Parenteral Topical
	By Distribution Channel Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
	By Region North America (By Drug, Disease, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Italy Spain Rest of Europe Asia Pacific (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region) Japan China India Australia Southeast Asia Rest of Asia Pacific Rest of the World (By Drug, Disease, Route of Administration, and Distribution Channel)